News
-
-
-
COMMUNIQUÉ DE PRESSE
Skyhawk Therapeutics Announces Nine Month Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington's Disease
Skyhawk Therapeutics reports positive interim results in Phase 1 Clinical Trial of SKY-0515 for Huntington's Disease, showing promising data on disease progression and safety